Subtopic Deep Dive

Sphingolipid Metabolism Dysregulation
Research Guide

What is Sphingolipid Metabolism Dysregulation?

Sphingolipid metabolism dysregulation refers to enzymatic imbalances in sphingolipid pathways, particularly elevated ceramide synthesis via CerS6, that drive insulin resistance, obesity, and metabolic syndrome.

This subtopic examines how obesity induces CerS6-dependent C16:0 ceramide production, promoting weight gain and glucose intolerance (Turpin-Nolan et al., 2014, 670 citations). In vivo manipulations reveal sphingolipids like ceramide and glucosylceramides as key mediators linking dyslipidemia to diabetes (Holland and Summers, 2008, 564 citations). Over 10 papers from the list address enzyme activities in obesity models and insulin signaling defects.

Curated Papers

Key Challenges

Why It Matters

Dysregulated sphingolipid metabolism connects lipid imbalances to type 2 diabetes and metabolic syndrome, with CerS6-derived C16:0 ceramide directly causing glucose intolerance in mouse models (Turpin-Nolan et al., 2014). Ceramide accumulation inhibits insulin signaling in skeletal muscle via PKCζ activation, as shown in palmitate-treated L6 cells (Powell et al., 2004). These links inform therapies targeting sphingomyelinase and kinase enzymes for obesity interventions (Holland and Summers, 2008; Sokołowska and Błachnio-Zabielska, 2019).

Key Research Challenges

Quantifying Ceramide Isoforms

Distinguishing C16:0 from other ceramide species in tissues remains difficult due to shotgun lipidomics limitations. Turpin-Nolan et al. (2014) used CerS6 knockout models to isolate effects, but broader isoform profiling needs higher resolution. This hinders pinpointing dysregulation drivers in human obesity.

Linking to Insulin Resistance

Mechanisms connecting sphingolipids to impaired insulin signaling vary by tissue and model. Powell et al. (2004) showed PKCζ mediation in muscle cells, while Holland and Summers (2008) highlighted in vivo enzyme manipulations. Causality requires multi-omics integration across species.

Translating to Human Disease

Mouse models like CerS6 knockouts do not fully recapitulate human metabolic syndrome sphingolipid profiles. Han et al. (2011) identified plasma sphingolipid shifts in Alzheimer's, suggesting similar needs for metabolic diseases. Clinical validation lags behind preclinical findings (Quinville et al., 2021).

Essential Papers

Obesity-Induced CerS6-Dependent C16:0 Ceramide Production Promotes Weight Gain and Glucose Intolerance

Sarah M. Turpin-Nolan, Hayley T. Nicholls, Diana M. Willmes et al. · 2014 · Cell Metabolism · 670 citations

Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism

William L. Holland, Scott A. Summers · 2008 · Endocrine Reviews · 564 citations

Obesity and dyslipidemia are risk factors for metabolic disorders including diabetes and cardiovascular disease. Sphingolipids such as ceramide and glucosylceramides, while being a relatively minor...

Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics

Xianlin Han, Steve Rozen, Stephen H. Boyle et al. · 2011 · PLoS ONE · 432 citations

In this prospective study, we used a sensitive multimodality platform to identify and characterize an essentially uniform but opposite pattern of disruption in sphingomyelin and ceramide mass level...

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer

Yi Xiao, Ding Ma, Yun‐Song Yang et al. · 2022 · Cell Research · 293 citations

Abstract Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the pola...

A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis

Brianna M. Quinville, Natalie M. Deschenes, Alex E. Ryckman et al. · 2021 · International Journal of Molecular Sciences · 290 citations

Sphingolipids are a specialized group of lipids essential to the composition of the plasma membrane of many cell types; however, they are primarily localized within the nervous system. The amphipat...

The Role of Ceramides in Insulin Resistance

Emilia Sokołowska, Agnieszka Błachnio‐Zabielska · 2019 · Frontiers in Endocrinology · 283 citations

Resistance to insulin is a pathophysiological state related to the decreased response of peripheral tissues to the insulin action, hyperinsulinemia and raised blood glucose levels caused by increas...

The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer’s Disease and Other Neurodegenerative Disorders

Kinga Czubowicz, Henryk Jęśko, P.L. Wencel et al. · 2019 · Molecular Neurobiology · 271 citations

Reading Guide

Foundational Papers

Start with Holland and Summers (2008, 564 citations) for in vivo sphingolipid-insulin links, then Turpin-Nolan et al. (2014, 670 citations) for CerS6 mechanisms, and Powell et al. (2004, 258 citations) for cellular insulin resistance pathways.

Recent Advances

Quinville et al. (2021, 290 citations) reviews homeostasis disruptions; Sokołowska and Błachnio-Zabielska (2019, 283 citations) details ceramide roles in resistance.

Core Methods

Shotgun lipidomics (Han et al., 2011), CerS6 knockout models (Turpin-Nolan et al., 2014), PKCζ inhibition assays (Powell et al., 2004).

How PapersFlow Helps You Research Sphingolipid Metabolism Dysregulation

Discover & Search

Research Agent uses searchPapers and citationGraph to map Turpin-Nolan et al. (2014) as the hub (670 citations) for CerS6-ceramide in obesity, then findSimilarPapers uncovers Holland and Summers (2008) on in vivo manipulations. exaSearch queries 'CerS6 insulin resistance mouse models' to retrieve 50+ related papers from 250M+ OpenAlex database.

Analyze & Verify

Analysis Agent applies readPaperContent to extract ceramide quantification methods from Turpin-Nolan et al. (2014), then runPythonAnalysis with pandas to compare lipidomics datasets across obesity papers. verifyResponse (CoVe) and GRADE grading confirm claims like PKCζ activation (Powell et al., 2004) with statistical verification of p-values from abstracts.

Synthesize & Write

Synthesis Agent detects gaps in human translation from mouse CerS6 data (Turpin-Nolan et al., 2014), flags contradictions between muscle (Powell et al., 2004) and systemic models (Holland and Summers, 2008). Writing Agent uses latexEditText, latexSyncCitations for 10 papers, latexCompile for review manuscripts, and exportMermaid for sphingolipid pathway diagrams.

Use Cases

"Analyze ceramide levels in Turpin-Nolan 2014 obesity data with stats"

Research Agent → searchPapers('Turpin-Nolan CerS6') → Analysis Agent → readPaperContent + runPythonAnalysis (NumPy/pandas for t-tests on C16:0 levels) → statistical output with p-values and plots.

"Write LaTeX review on sphingolipid dysregulation in insulin resistance"

Synthesis Agent → gap detection across Holland 2008 and Sokołowska 2019 → Writing Agent → latexEditText(draft) → latexSyncCitations(10 papers) → latexCompile → PDF with pathway figures.

"Find code for shotgun lipidomics in sphingolipid papers"

Research Agent → paperExtractUrls(Han et al. 2011) → Code Discovery → paperFindGithubRepo → githubRepoInspect → R script for plasma sphingolipidome analysis.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers('sphingolipid dysregulation obesity') → citationGraph → DeepScan (7-step: read 20 papers, CoVe checkpoints) → structured report on CerS6 mechanisms. Theorizer generates hypotheses linking ceramide to diabetes from Powell et al. (2004) and Turpin-Nolan et al. (2014), outputting mermaid diagrams of signaling paths.

Try Doxa for Sphingolipid Metabolism Dysregulation Research

Frequently Asked Questions

What defines sphingolipid metabolism dysregulation?

Enzymatic imbalances elevating ceramides like C16:0 via CerS6 in obesity, leading to insulin resistance (Turpin-Nolan et al., 2014).

What methods study this dysregulation?

In vivo knockouts (Turpin-Nolan et al., 2014), shotgun lipidomics (Han et al., 2011), and palmitate-treated cell models (Powell et al., 2004) quantify enzyme activities and lipid levels.

What are key papers?

Turpin-Nolan et al. (2014, 670 citations) on CerS6-ceramide in obesity; Holland and Summers (2008, 564 citations) on sphingolipids in metabolic disease.